Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659880 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL12316010 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL27626477 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1713614 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL739575 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1263214 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL523698 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL3659883 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL522714 | 0.90 | KMT2A (0.81) | KMT2AMAPTMAPK1ALOX15POLB | |
| SCHEMBL522715 | 0.90 | KMT2A (0.81) | KMT2AMAPTMAPK1ALOX15POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2928888-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | Hutchison Medipharma Limited (CN) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-0559774-B1 | INDIVIDUAL STEREOISOMERS OF 7- 3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0909759-A2 | Individual stereoisomers of 7-(3-aminoalkyl)-1-pyrrolidinyl)-quinolones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5864039-A | THERAPEUTIC TREATMENT OF VARIOUS GASTROINTESTINAL DISEASES, CENTRAL NERVOUS DISORDERS, CARDIOVASCULAR DISORDERS, URINARY DISEASES, UROGENITAL DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-01-26 | — | — | US | disclosed |
| US-5633264-A | Individual stereoisomers of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-Quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| EP-0774460-A1 | BENZOIC ACID COMPOUND AND USE THEREOF AS MEDICINE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| US-5563155-A | QUINOLONE ANTIBIOTICS WITH INCREASED EFFICACY, REDUCED SIDE EFFECTS | WARNER-LAMBERT COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| US-5461165-A | Individual stereoisomers of intermediates of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| US-5344940-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0559774-A1 | INDIVIDUAL STEREOISOMERS OF 7- 3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009596-A1 | INDIVIDUAL STEREOISOMERS OF 7-[3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | KMT2A 597/4885MAPT 3971/4885MAPK1 935/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | KMT2A 597/4885MAPT 3971/4885MAPK1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.